REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Triple therapy takes on aggressive blood cancer
Disease control OngoingThis phase 2 trial is testing whether adding a personalized cell therapy (liso-cel) to two existing drugs (nivolumab and ibrutinib) can help people with Richter's transformation, a rare and aggressive blood cancer. The study plans to enroll 9 participants and will measure how man…
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Triple-Drug attack aims to wipe out Hard-to-Treat leukemia
Disease control OngoingThis phase 2 trial tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the …
Matched conditions: REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC